**Primary treatment phase**

- Pre-treatment evaluation
- Weeks –4 –3 –2 –1

**Maintenance treatment phase**

- L-BLP25 arm: 930 µg SC
- Maintenance treatment continued until progressive disease or discontinuation

**Follow-up**

- Control arm: placebo* SC

---

*Cyclophosphamide pretreatment (300 mg/m² [max 600 mg] single IV infusion)*

- 3 d
- Sodium chloride (0.9% IV)

---

Tumour imaging** (≤28 d prior to randomization)

Tumour imaging** (according to local hospital standards)

---

*Formulated to provide the same carrier lipid matrix as L-BLP25, but without the adjuvant (monophosphoryl lipid A) and BLP25 lipopeptide.

**Computed tomography and/or magnetic resonance imaging.

Each syringe represents four SC injections of L-BLP25 or placebo at four anatomical sites (deltoid or triceps region of the upper arms and the left and right anterolateral aspects of the abdomen).

The syringe represents a single IV infusion of cyclophosphamide or saline substitute for cyclophosphamide.

d, days; IV, intravenous; R, randomization; SC, subcutaneous.